Mark R. Gilbert, MD, a professor of neuro-oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

Several components of the 0825 trial are still under evaluation, including a composite interpretation of progression-free survival that includes data on quality of life and neurocognitive function. Gilbert believes these endpoints are a pivotal component that should be included as part of the composite analysis for all clinical trials.

Additionally, a secondary analysis of MGMT and a 9 gene molecular profile is still under way to determine if patients can be identified who benefited the most from treatment with bevacizumab in the first-line setting.

View more from the 2013 ASCO Annual Meeting

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Brain Cancer

 Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

ASCO Annual Meeting

Mark R. Gilbert, MD, from the University of Texas MD Anderson Cancer Center in Houston, Texas, discusses findings from the RTOG 0825 phase III trial evaluating bevacizumab in patients with newly diagnosed glioblastoma.

Dr. Gilbert Describes Ongoing RTOG 0825 Trial Analyses